Abstract 438P
Background
Immune checkpoint inhibitors (ICIs) demonstrate efficacy against various cancers by activating the immune response against neoplasia. On the other hand, ICI-related myocarditis, which has a high mortality rate, is known to occur as adverse event. Therefore, safe ICI therapy should be established worldwide. In the present study, we developed a mouse model of ICI-related myocarditis and evaluated the efficacy of vitamin D, which exerts therapeutic effects on autoimmune myocarditis.
Methods
PD-1 knockout (PD-1KO) mice were treated with the myocardial myosin peptide and pertussis toxin to create a mouse model of ICI-related myocarditis. After 21 days of myocardial myosin peptide administration, their hearts were dissected and evaluated for the development of myocarditis. In addition, vitamin D, a candidate drug, was administered to the model mice every other day to evaluate its effect on the severity of myocarditis.
Results
Administering the myocardial myosin peptide to PD-1KO mice resulted in infiltration of inflammatory cells into the myocardial tissue and progressive myocardial fibrosis. Fluorescent immunostaining showed infiltration of CD4⁺ and CD8⁺ T cells in the myocardial tissue. Inflammatory cell infiltration was significantly suppressed in the vitamin D-treated group than in the vehicle group, as was CD4⁺ and CD8⁺ T cell infiltration. There was a trend toward suppression of myocardial fibrosis with vitamin D administration, although without statistical significance.
Conclusions
By administering the myocardial myosin peptide to PD-1KO mice, we generated a simple and reproducible experimental model of ICI-related myocarditis. Furthermore, vitamin D attenuated the infiltration of inflammatory cells and prevented the onset of ICI-related myocarditis in the model mice. The application of vitamin D as a prophylactic agent for ICI-related myocarditis should be investigated in the future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Japan Society for the Promotion of Science.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract